0001735438--12-312020Q3falseP12M3841216300P36M0.3333367919060.250.50000001735438us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001735438us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001735438us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300001735438us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001735438us-gaap:AdditionalPaidInCapitalMembermgtx:AtMarketOfferingMember2020-07-012020-09-300001735438us-gaap:AdditionalPaidInCapitalMembermgtx:PublicPlacementMember2019-07-012019-09-300001735438us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2019-01-012019-03-310001735438us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001735438us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001735438us-gaap:CommonStockMember2020-07-012020-09-300001735438us-gaap:CommonStockMember2020-01-012020-03-310001735438us-gaap:CommonStockMember2019-04-012019-06-300001735438us-gaap:CommonStockMembermgtx:AtMarketOfferingMember2020-07-012020-09-300001735438us-gaap:CommonStockMembermgtx:PublicPlacementMember2019-07-012019-09-300001735438us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2019-01-012019-03-310001735438us-gaap:CommonStockMember2019-07-012019-09-300001735438us-gaap:CommonStockMember2020-04-012020-06-300001735438us-gaap:RetainedEarningsMember2020-09-300001735438us-gaap:AdditionalPaidInCapitalMember2020-09-300001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001735438us-gaap:RetainedEarningsMember2020-06-300001735438us-gaap:AdditionalPaidInCapitalMember2020-06-300001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000017354382020-06-300001735438us-gaap:RetainedEarningsMember2020-03-310001735438us-gaap:AdditionalPaidInCapitalMember2020-03-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100017354382020-03-310001735438us-gaap:RetainedEarningsMember2019-12-310001735438us-gaap:AdditionalPaidInCapitalMember2019-12-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001735438us-gaap:RetainedEarningsMember2019-09-300001735438us-gaap:AdditionalPaidInCapitalMember2019-09-300001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001735438us-gaap:RetainedEarningsMember2019-06-300001735438us-gaap:AdditionalPaidInCapitalMember2019-06-300001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-3000017354382019-06-300001735438us-gaap:RetainedEarningsMember2019-03-310001735438us-gaap:AdditionalPaidInCapitalMember2019-03-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-3100017354382019-03-310001735438us-gaap:RetainedEarningsMember2018-12-310001735438us-gaap:AdditionalPaidInCapitalMember2018-12-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001735438us-gaap:CommonStockMember2020-09-300001735438us-gaap:CommonStockMember2020-06-300001735438us-gaap:CommonStockMember2020-03-310001735438us-gaap:CommonStockMember2019-12-310001735438us-gaap:CommonStockMember2019-09-300001735438us-gaap:CommonStockMember2019-06-300001735438us-gaap:CommonStockMember2019-03-310001735438us-gaap:CommonStockMember2018-12-310001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2020-03-060001735438us-gaap:RestrictedStockUnitsRSUMembermgtx:SeniorManagementMember2020-01-080001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2020-03-062020-03-060001735438us-gaap:RestrictedStockUnitsRSUMembermgtx:SeniorManagementMember2020-01-082020-01-0800017354382019-01-012019-12-310001735438srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-09-300001735438srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-09-300001735438srt:MinimumMemberus-gaap:EmployeeStockOptionMember2019-01-012019-09-300001735438srt:MaximumMemberus-gaap:EmployeeStockOptionMember2019-01-012019-09-300001735438us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001735438mgtx:SeniorManagementMember2019-01-012019-12-310001735438mgtx:AcquisitionOfEmrySMembermgtx:RestrictedOrdinarySharesMembermgtx:SecondAnniversaryOfClosingDateMember2020-04-092020-04-090001735438mgtx:AcquisitionOfEmrySMembermgtx:RestrictedOrdinarySharesMembermgtx:FirstAnniversaryOfClosingDateMember2020-04-092020-04-090001735438us-gaap:RestrictedStockUnitsRSUMembermgtx:ThirdAnniversaryMember2020-01-012020-09-300001735438us-gaap:RestrictedStockUnitsRSUMembermgtx:SecondAnniversaryMember2020-01-012020-09-300001735438us-gaap:RestrictedStockUnitsRSUMembermgtx:FourthAnniversaryMember2020-01-012020-09-300001735438mgtx:FirstAnniversaryMember2020-01-012020-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMember2018-06-072018-06-070001735438srt:DirectorMember2020-01-012020-09-300001735438mgtx:OverThreeYearsMember2020-01-012020-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMemberus-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMember2020-07-012020-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMemberus-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMember2020-01-012020-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMemberus-gaap:GeneralAndAdministrativeExpenseMember2019-07-012019-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMember2019-07-012019-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMemberus-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMember2019-01-012019-09-3000017354382020-04-092020-04-090001735438mgtx:UclConsultantsLimitedMembermgtx:MasterServicesAgreementMember2020-07-012020-09-300001735438mgtx:LicenseAgreementMember2020-07-012020-09-300001735438mgtx:UclConsultantsLimitedMembermgtx:MasterServicesAgreementMember2020-01-012020-09-300001735438mgtx:LicenseAgreementMember2020-01-012020-09-300001735438mgtx:LicenseAgreementForInheritedRetinalDiseaseProgramsRelatedToCngb3Member2020-01-012020-09-300001735438mgtx:UclConsultantsLimitedMembermgtx:MasterServicesAgreementMember2019-07-012019-09-300001735438mgtx:LicenseAgreementMember2019-07-012019-09-300001735438mgtx:UclConsultantsLimitedMembermgtx:MasterServicesAgreementMember2019-01-012019-09-300001735438mgtx:LicenseAgreementMember2019-01-012019-09-300001735438mgtx:LicenseAgreementForInheritedRetinalDiseaseProgramsRelatedToCngb3Member2019-01-012019-09-300001735438mgtx:AtMarketOfferingMember2020-07-012020-09-300001735438us-gaap:CommonStockMember2020-01-012020-09-300001735438mgtx:PublicPlacementMember2019-07-012019-09-300001735438us-gaap:CommonStockMember2019-01-012019-09-300001735438us-gaap:PrivatePlacementMember2019-01-012019-03-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001735438us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001735438us-gaap:OperatingIncomeLossMembermgtx:KadmonCorporationLlcMember2020-07-012020-09-300001735438mgtx:AreEastRiverScienceParkLlcMember2020-07-012020-09-300001735438us-gaap:OperatingIncomeLossMembermgtx:KadmonCorporationLlcMember2020-01-012020-09-300001735438us-gaap:OperatingIncomeLossMembermgtx:KadmonCorporationLlcMember2019-07-012019-09-300001735438mgtx:AreEastRiverScienceParkLlcMember2019-07-012019-09-300001735438us-gaap:OperatingIncomeLossMembermgtx:KadmonCorporationLlcMember2019-01-012019-09-300001735438mgtx:AreEastRiverScienceParkLlcMember2019-01-012019-09-300001735438country:US2020-09-300001735438country:NL2020-09-300001735438country:IE2020-09-300001735438country:GB2020-09-300001735438country:US2019-12-310001735438country:NL2019-12-310001735438country:GB2019-12-310001735438us-gaap:RetainedEarningsMember2020-07-012020-09-300001735438us-gaap:RetainedEarningsMember2020-04-012020-06-3000017354382020-04-012020-06-300001735438us-gaap:RetainedEarningsMember2020-01-012020-03-3100017354382020-01-012020-03-310001735438us-gaap:RetainedEarningsMember2019-07-012019-09-300001735438us-gaap:RetainedEarningsMember2019-04-012019-06-3000017354382019-04-012019-06-300001735438us-gaap:RetainedEarningsMember2019-01-012019-03-3100017354382019-01-012019-03-310001735438mgtx:AreEastRiverScienceParkLlcMember2020-05-310001735438us-gaap:ForeignExchangeContractMember2020-01-012020-09-300001735438us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001735438mgtx:RestrictedCashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001735438mgtx:AssetRetirementObligationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001735438us-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001735438mgtx:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001735438mgtx:AssetRetirementObligationsMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300001735438mgtx:RestrictedCashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001735438mgtx:AssetRetirementObligationsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001735438mgtx:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001735438mgtx:AssetRetirementObligationsMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001735438us-gaap:EmployeeStockOptionMember2020-09-300001735438us-gaap:RestrictedStockUnitsRSUMember2020-09-300001735438us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001735438mgtx:UclConsultantsLimitedMembermgtx:MasterServicesAgreementMember2020-09-300001735438mgtx:AccountsPayableAndAccruedExpensesMembermgtx:UclConsultantsLimitedMembermgtx:MasterServicesAgreementMember2020-09-300001735438mgtx:KadmonCorporationLlcMember2020-09-300001735438mgtx:AccountsPayableAndAccruedExpensesMembermgtx:UclConsultantsLimitedMembermgtx:MasterServicesAgreementMember2019-12-310001735438mgtx:KadmonCorporationLlcMember2019-12-310001735438us-gaap:ForeignExchangeContractMember2020-09-300001735438mgtx:OthersComprehensiveIncomeMember2019-07-012019-09-300001735438mgtx:BenefitForIncomeTaxMember2019-07-012019-09-300001735438mgtx:OthersComprehensiveIncomeMember2019-01-012019-09-300001735438mgtx:BenefitForIncomeTaxMember2019-01-012019-09-300001735438mgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2020-09-300001735438mgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-12-310001735438mgtx:RiboswitchResearchMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2018-10-160001735438us-gaap:IPOMember2019-08-070001735438mgtx:JohnsonAndJohnsonInnovationJjdcIncMemberus-gaap:PrivatePlacementMember2019-02-270001735438us-gaap:PrivatePlacementMember2019-02-270001735438mgtx:AcquisitionOfEmrySMemberus-gaap:CommonStockMember2020-04-090001735438mgtx:AcquisitionOfEmrySMemberus-gaap:CommonStockMembermgtx:OnClosingDateMember2020-04-092020-04-090001735438mgtx:AcquisitionOfEmrySMembermgtx:RestrictedOrdinarySharesMembermgtx:OnClosingDateMember2020-04-092020-04-090001735438mgtx:AcquisitionOfEmrySMemberus-gaap:CommonStockMember2020-04-092020-04-090001735438mgtx:AcquisitionOfEmrySMember2020-04-0900017354382019-09-3000017354382018-12-310001735438us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001735438us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001735438us-gaap:RestrictedStockMember2019-01-012019-09-300001735438us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001735438us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001735438us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001735438us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001735438us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001735438us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300001735438us-gaap:GeneralAndAdministrativeExpenseMember2019-07-012019-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300001735438us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-09-300001735438us-gaap:RestrictedStockMember2018-06-070001735438mgtx:AcquisitionOfEmrySMemberus-gaap:CommonStockMembermgtx:FollowingClosingDateMember2020-04-092020-04-090001735438us-gaap:AdditionalPaidInCapitalMembermgtx:LicenseAgreementMember2019-01-012019-03-310001735438mgtx:LicenseAgreementMember2019-01-012019-03-310001735438us-gaap:CommonStockMembermgtx:LicenseAgreementMember2019-03-212019-03-210001735438us-gaap:CommonStockMembermgtx:LicenseAgreementMember2019-01-012019-03-310001735438mgtx:LicenseAgreementForInheritedRetinalDiseaseProgramsRelatedToCngb3Member2018-03-152018-03-150001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMember2019-12-310001735438mgtx:SeniorManagementMember2018-12-310001735438mgtx:UCLBusinessPLCMembermgtx:LicenseAgreementMember2020-09-300001735438mgtx:UCLBusinessPLCMembermgtx:LicenseAgreementMember2015-02-040001735438mgtx:AtMarketOfferingMember2020-01-012020-09-300001735438mgtx:ClinicalInheritedRetinalDiseaseProductCandidateDevelopmentMemberus-gaap:CollaborativeArrangementMember2019-01-302019-01-300001735438srt:MaximumMembermgtx:ClinicalInheritedRetinalDiseaseProductCandidateDevelopmentMember2019-01-302019-01-300001735438mgtx:UclConsultantsLimitedMembermgtx:MasterServicesAgreementMember2016-10-232016-10-230001735438us-gaap:ResearchAndDevelopmentExpenseMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300001735438us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300001735438mgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300001735438us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300001735438us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300001735438mgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300001735438us-gaap:PrepaidExpensesAndOtherCurrentAssetsMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300001735438mgtx:UCLBusinessPLCMembermgtx:LicenseAgreementMember2020-03-232020-03-230001735438mgtx:ResearchInheritedRetinalProductCandidatesDevelopmentMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-302019-01-300001735438mgtx:ClinicalInheritedRetinalDiseaseProductCandidateDevelopmentMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-302019-01-300001735438mgtx:MeiraIrelandMembermgtx:ShannonFreeZoneMember2020-08-042020-08-040001735438mgtx:KadmonCorporationLlcMember2020-07-012020-09-300001735438mgtx:KadmonCorporationLlcMember2020-01-012020-09-300001735438mgtx:KadmonCorporationLlcMember2019-07-012019-09-300001735438mgtx:KadmonCorporationLlcMember2019-01-012019-09-300001735438mgtx:AreEastRiverScienceParkLlcMember2019-12-310001735438mgtx:AreEastRiverScienceParkLlcMember2020-09-300001735438us-gaap:RestrictedStockMembermgtx:SeniorManagementMember2018-06-070001735438mgtx:MeiraIrelandMembermgtx:ShannonFreeZoneMember2020-08-040001735438mgtx:AreEastRiverScienceParkLlcMember2020-01-012020-09-300001735438mgtx:UCLBusinessPLCMembermgtx:LicenseAgreementMember2015-02-042015-02-040001735438mgtx:UCLBusinessPLCMembermgtx:LicenseAgreementForInheritedRetinalDiseaseProgramsRelatedToCngb3Member2018-03-152018-03-150001735438srt:MinimumMember2020-01-012020-09-300001735438srt:MaximumMember2020-01-012020-09-3000017354382020-07-012020-09-3000017354382019-07-012019-09-300001735438mgtx:UCLBusinessPLCMembermgtx:LicenseAgreementMember2020-03-230001735438mgtx:RiboswitchResearchMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2018-10-162018-10-160001735438mgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300001735438mgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-012019-12-310001735438us-gaap:IPOMember2019-08-072019-08-070001735438us-gaap:PrivatePlacementMember2019-02-272019-02-270001735438mgtx:ResearchDevelopmentAndCommercializationOfGeneTherapiesMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-302019-01-300001735438mgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-302019-01-300001735438mgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-3000017354382020-08-2700017354382020-08-042020-08-0400017354382019-01-012019-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMembermgtx:RiboswitchResearchMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300001735438us-gaap:ResearchAndDevelopmentExpenseMembermgtx:RiboswitchResearchMembermgtx:JanssenPharmaceuticalsIncMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300001735438mgtx:AtMarketOfferingMember2019-07-012019-07-3100017354382020-09-3000017354382019-12-3100017354382020-10-3100017354382020-01-012020-09-30mgtx:propertyxbrli:sharesiso4217:USDiso4217:GBPmgtx:Programmgtx:contractmgtx:itemmgtx:leasexbrli:pureiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                  to                 

Commission File Number: 001-38520

MeiraGTx Holdings plc

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands

    

98-1448305

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

450 East 29th Street, 14th Floor

New York, NY

10016

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (646860-7985

Not Applicable

(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

     

Trading
Symbol(s)

    

Name of each exchange
on which registered

Ordinary Shares,
$0.00003881 par value per share

MGTX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer    ☐

    

Accelerated filer        

Non-accelerated filer    ☐

Small reporting company        

Emerging growth Company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes      No  

As of October 31, 2020, the registrant had 38,412,163 ordinary shares, $0.00003881 par value per share, outstanding.

Table of Contents

Forward-Looking Statements

This Quarterly Report on Form 10-Q (the “Form 10-Q”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 10-Q that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding expectations regarding meetings with global regulatory authorities and the FDA, product pipeline, anticipated product benefits, goals and strategic priorities, product candidate development and status and expectations relating to clinical trials, growth expectations or targets and pre-clinical and clinical data expectations in respect of collaborations, including, in each case, in light of the COVID-19 pandemic, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under Item 1A. “Risk Factors” in this Form 10-Q. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 10-Q. Any such forward-looking statements represent management’s estimates as of the date of this Form 10-Q. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Form 10-Q.

Preliminary Notes

Unless the context otherwise requires, references in this Form 10-Q to “Meira,” “we,” “us”, “our” and “the Company” refer to MeiraGTx Holdings plc and its subsidiaries.

i

Table of Contents

Table of Contents

Page

PART I.

FINANCIAL INFORMATION

1

Item 1.

Financial Statements (Unaudited)

1

Condensed Consolidated Balance Sheets

1

Condensed Consolidated Statements of Operations and Comprehensive Loss

2

Condensed Consolidated Statement of Shareholders’ Equity

3

Condensed Consolidated Statement of Shareholders’ Equity

4

Condensed Consolidated Statements of Cash Flows

5

Notes to Condensed Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

29

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

40

Item 4.

Controls and Procedures

40

PART II.

OTHER INFORMATION

41

Item 1.

Legal Proceedings

41

Item 1A.

Risk Factors

41

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

98

Item 3.

Defaults Upon Senior Securities

98

Item 4.

Mine Safety Disclosures

98

Item 5.

Other Information

98

Item 6.

Exhibits

99

Signatures

101

ii

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

September 30, 

December 31, 

    

2020

    

2019

ASSETS

 

  

 

  

CURRENT ASSETS:

 

  

 

  

Cash and cash equivalents

$

179,084,386

$

227,233,384

Restricted cash

 

250,526

 

Accounts receivable - related party

26,639,805

23,337,377

Prepaid expenses

 

4,001,502

 

4,464,085

Tax incentive receivable

7,087,253

11,974,437

Other current assets

 

818,671

 

1,970,585

Total Current Assets

 

217,882,143

 

268,979,868

Property and equipment, net

 

34,820,814

 

23,858,108

Security deposits

 

737,720

 

951,138

In-process research and development

810,357

777,655

Restricted cash

123,376

Other assets

203,255

195,053

Right-of-use assets

38,591,434

29,002,448

TOTAL ASSETS

$

293,045,723

$

323,887,646

LIABILITIES AND SHAREHOLDERS' EQUITY

 

  

 

  

CURRENT LIABILITIES:

 

  

 

  

Accounts payable

$

5,195,937

$

3,759,339

Accrued expenses

 

15,563,482

 

18,083,757

Lease obligations, current

 

2,116,018

 

1,674,210

Deferred revenue - related party, current

 

23,715,116

 

25,678,515

Other current liabilities

 

17,639

 

Total Current Liabilities

 

46,608,192

 

49,195,821

Deferred revenue - related party

 

48,279,463

 

60,535,576

Lease obligations

 

17,127,159

 

21,504,340

Asset retirement obligations

 

1,741,407

 

1,654,755

Deferred income tax liability

203,255

195,053

TOTAL LIABILITIES

 

113,959,476

 

133,085,545

COMMITMENTS

 

  

 

  

SHAREHOLDERS' EQUITY:

 

  

 

  

Ordinary Shares, $0.00003881 par value, 1,288,327,750 authorized,
38,412,163 and 36,791,906 shares issued and outstanding at September 30, 2020
and December 31, 2019, respectively

 

1,491

 

1,429

Capital in excess of par value

 

431,103,319

 

395,630,666

Accumulated other comprehensive loss

 

(1,451,753)

 

(1,794,042)

Accumulated deficit

 

(250,566,810)

 

(203,035,952)

Total Shareholders' Equity

 

179,086,247

 

190,802,101

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$

293,045,723

$

323,887,646

See Notes to Condensed Consolidated Financial Statements

1

Table of Contents

MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

For the Three-Month Periods Ended September 30, 

For the Nine-Month Periods Ended September 30, 

    

2020

    

2019

    

2020

    

2019

License revenue - related party

$

5,091,832

$

3,582,586

$

11,775,113

$

6,349,222

Operating expenses:

General and administrative

8,896,111

9,874,810

32,199,515

31,811,456

Research and development

 

4,626,085

 

4,614,446

 

28,911,490

 

27,362,432

Total operating expenses

 

13,522,196

 

14,489,256

 

61,111,005

 

59,173,888

Loss from operations

 

(8,430,364)

 

(10,906,670)

 

(49,335,892)

 

(52,824,666)

Other non-operating income (expense):

Foreign currency gain

 

1,875,427

115,470

766,860

3,117,047

Interest income

 

158,346

959

1,141,321

40,686

Interest expense

 

(35,136)

(9,283)

(103,147)

(28,311)

Loss before income taxes

 

(6,431,727)

(10,799,524)

 

(47,530,858)

 

(49,695,244)

Benefit for income taxes

 

338,670

 

 

430,060

Net loss

 

(6,431,727)

 

(10,460,854)

 

(47,530,858)

 

(49,265,184)

Other comprehensive (loss) income:

Foreign currency translation, net of tax of $0 and $338,670 for the three-month periods ended September 30, 2020 and 2019, respectively and $0 and $430,060 for the nine-month periods ended September 30, 2020 and 2019, respectively

 

(4,121,227)

1,653,507

342,289

2,099,706

Total comprehensive loss

$

(10,552,954)

$

(8,807,347)

$

(47,188,569)

$

(47,165,478)

Net loss

$

(6,431,727)

$

(10,460,854)

$

(47,530,858)

$

(49,265,184)

Basic and diluted net loss per ordinary share

$

(0.17)

$

(0.30)

$

(1.29)

$

(1.53)

Weighted-average number of ordinary shares outstanding

 

37,223,375

34,663,623

36,940,372

32,111,733

See Notes to Condensed Consolidated Financial Statements

2

Table of Contents

MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

FOR THE PERIOD ENDED SEPTEMBER 30, 2020

(unaudited)

Shareholders’ Equity

Accumulated Other

Total

Ordinary

Capital in Excess

Comprehensive

Accumulated

Shareholders'

    

Shares

    

Amount

    

of Par Value

    

(Loss) Income

    

Deficit

    

Equity

Balance at December 31, 2019

 

36,791,906

$

1,429

$

395,630,666

$

(1,794,042)

$

(203,035,952)

$

190,802,101

Exercise of share options

26,010

 

1

 

175,076

 

 

 

175,077

Share-based compensation

 

 

 

5,682,881

 

 

 

5,682,881

Foreign currency translation

 

 

 

 

3,945,924

 

 

3,945,924

Net loss for the three-month period ended March 31, 2020

 

 

 

 

 

(15,681,197)

 

(15,681,197)

Balance at March 31, 2020

 

36,817,916

$

1,430

$

401,488,623

$

2,151,882

$

(218,717,149)

$

184,924,786

Share-based compensation

5,056,069

5,056,069

Issuance of shares in connection with asset acquisitions

544,500

21

7,684,980

7,685,001

Foreign currency translation

517,592

517,592

Net loss for the three-month period ended June 30, 2020

(25,417,934)

(25,417,934)

Balance at June 30, 2020

37,362,416

$

1,451

$

414,229,672

$

2,669,474

$

(244,135,083)

$

172,765,514

Exercise of share options

56,299

1

478,231

478,232

Share-based compensation

3,737,919

3,737,919

Issuance of shares in at-the-market offering, net of issuance costs of $505,650

993,448

39

12,657,497

12,657,536

Foreign currency translation

(4,121,227)

(4,121,227)

Net loss for the three-month period ended September 30, 2020

(6,431,727)

(6,431,727)

Balance at September 30, 2020

38,412,163

$

1,491

$

431,103,319

$

(1,451,753)

$

(250,566,810)

$

179,086,247

See Notes to Condensed Consolidated Financial Statements

3

Table of Contents

MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

FOR THE PERIOD ENDED SEPTEMBER 30, 2019

(unaudited)

Shareholders' Equity

Accumulated Other

Total

Ordinary

Capital in Excess

Comprehensive

Accumulated

Shareholders'

    

Shares

    

Amount

    

of Par Value

    

Income (Loss)

    

Deficit

    

Equity

Balance at December 31, 2018

 

27,386,632

$

1,064

$

229,054,460

$

293,666

$

(148,289,717)

$

81,059,473

Issuance of ordinary shares in connection with a license agreement

 

158,832

6

1,966,334

1,966,340

Sale of ordinary shares in connection with private placement, net of issuance costs of $2,426,953

 

5,797,102

225

77,572,822

77,573,047

Share-based compensation

 

2,934,991

2,934,991

Foreign currency translation

 

(1,133,683)

(1,133,683)

Net loss for the three-month period ended March 31, 2019

 

(17,981,918)

(17,981,918)

Balance at March 31, 2019

 

33,342,566

$

1,295

$

311,528,607

$

(840,017)

$

(166,271,635)

$

144,418,250

Exercise of share options

225

1,267

1,267

Share-based compensation

4,386,123

4,386,123

Foreign currency translation, net of income taxes

1,579,882

1,579,882

Net loss for the three-month period ended June 30, 2019

(20,822,412)

(20,822,412)

Balance at June 30, 2019

33,342,791

$

1,295

$

315,915,997

$

739,865

$

(187,094,047)

$

129,563,110

Sale of ordinary shares in connection with public offering, net of issuance costs of $5,042,795

3,200,000

124

70,157,088

70,157,212

Issuance of ordinary shares in connection with payables

19,807

1

421,499

421,500

Exercise of share options

9,124

53,344

53,344

Share-based compensation

3,505,551

3,505,551

Foreign currency translation, net of income taxes of $338,670

1,653,507

1,653,507

Net loss for the three-month period ended September 30, 2019

(10,460,854)

(10,460,854)

Balance at September 30, 2019

36,571,722

$

1,420

$

390,053,479

$

2,393,372

$

(197,554,901)

$

194,893,370

See Notes to Condensed Consolidated Financial Statements

4

Table of Contents

MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

For the Nine Months Ended September 30, 

    

2020

    

2019

Cash flows from operating activities:

 

  

 

  

Net loss

$

(47,530,858)

$

(49,265,184)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

 

 

Ordinary shares issued in connection with license agreement

 

 

1,966,340

Share-based compensation expense

 

14,476,869

 

10,826,665

Foreign currency gain

 

(766,860)

 

(3,117,047)

Depreciation

 

2,820,857

 

1,569,098

Lease obligations

30,447

304,713

Loss on disposal of equipment, furniture and fixtures

115,854

Gain on termination of lease liability

(143,589)

Amortization of interest on asset retirement obligations

 

100,847

 

7,861

Issuance of shares in connection with asset acquisition

 

7,685,001

 

Benefit for income taxes

 

 

(430,060)

(Increase) decrease in operating assets:

 

 

Accounts receivable - related party

(3,725,304)

Prepaid expenses

 

535,206

 

(4,413,356)

Tax incentive receivable

4,628,464

Other current assets

 

1,105,550

 

(6,358,738)

Security deposits

 

190,839

 

(745,275)

Increase (decrease) in operating liabilities:

 

 

Accounts payable

 

480,850

 

1,415,012

Accrued expenses

 

(2,634,475)

 

(2,428,405)

Other current liabilities

 

 

(436,161)

Deferred revenue - related party

 

(11,775,113)

 

93,120,824

Net cash (used in) provided by operating activities

 

(34,405,415)

 

42,016,287

Cash flows from investing activities:

 

  

 

  

Purchase of property and equipment

 

(12,908,918)

 

(4,230,740)

Payment for right of use asset

(13,876,778)

Net cash used in investing activities

 

(26,785,696)

 

(4,230,740)

Cash flows from financing activities:

 

  

 

  

Payments on lease obligations - financing leases

 

(19,339)

 

(17,923)

Exercise of share options

 

653,309

 

54,611

Proceeds from the issuance of ordinary shares

 

13,163,186

 

155,200,007

Issuance costs in connection with ordinary shares

 

(505,650)

 

(7,469,748)

Net cash provided by financing activities

 

13,291,506

 

147,766,947

Net (decrease) increase in cash, cash equivalents and restricted cash

 

(47,899,605)

 

185,552,494

Effect of exchange rate changes on cash

 

(122,243)

 

(302,046)

Cash, cash equivalents and restricted cash at beginning of period

 

227,356,760

 

68,203,551

Cash, cash equivalents and restricted cash at end of period

$

179,334,912

$

253,453,999

Supplemental disclosure of non-cash transactions:

 

  

 

  

Issuance of shares in connection with asset acquisition

$

7,685,001

$

Issuance of shares in connection with a license agreement

$

$

1,966,340

Fixed asset acquisition included in accounts payable and accrued expenses at end of period

$

1,191,917

$

Issuance of shares in connection with payables

$

$

421,500

Lease obligations for right-of-use asset

$

$

22,932,582

Supplemental disclosure of cash flow information:

 

  

 

  

Cash paid for interest

$

136

$

1,219

See Notes to Condensed Consolidated Financial Statements

5

Table of Contents

MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.       Organization and Basis of Presentation:

The Company

MeiraGTx Holdings plc and subsidiaries (the “Company” or “Meira Holdings”), an exempted company incorporated under the laws of the Cayman Islands, is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs.  The Company has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology.  Led by an experienced management team, the Company has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications.  The Company’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia.  Though initially focusing on the eye, central nervous system and salivary gland, the Company intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. The Company also owns and operates a current good manufacturing practices, or cGMP, multi-product, multi-viral vector manufacturing facility in London, United Kingdom, which includes fill and finish capabilities and can supply the Company’s clinical and potential commercial material. Additionally, on August 4, 2020, the Company entered into agreements to acquire its second cGMP viral vector manufacturing facility and its first cGMP plasmid production facility in Shannon, Ireland to expand its manufacturing and supply chain capabilities. The Company closed on the acquisition of the first building in August 2020 and expects to close on the acquisition of the second building when the building structure is completed, which is expected to occur in December 2020.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Interim Financial Statements

The accompanying condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete consolidated financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make the condensed consolidated financial statements not misleading. Operating results for the nine-month period ended September 30, 2020 are not necessarily indicative of the final results that may be expected for the year ending December 31, 2020. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Form 10-K”).

Liquidity

The Company has not yet achieved profitable operations. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, and commercialization of the Company’s product candidates will require significant additional financing. The Company’s accumulated deficit at September 30, 2020 totaled $250,566,810, and management expects to incur substantial losses in future periods. The success of the Company is subject to certain risks and uncertainties, including, among others: uncertainty of product development; competition in the Company’s field of use;

6

Table of Contents

uncertainty of capital availability; uncertainty in the Company’s ability to enter into agreements with collaborative partners; dependence on third parties; and dependence on key personnel. For the nine-months ended September 30, 2020, the Company used $34,405,415 in cash flows from operations and there are no assurances that the Company will generate positive cash flows in the future. Additionally, there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates.

As of September 30, 2020, the Company had cash, cash equivalents and restricted cash in the amount of $179,334,912, which consisted of depository accounts. On January 30, 2019, the Company entered into a collaboration, option and license agreement with Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceuticals Companies of Johnson & Johnson (the “Collaboration Agreement”), for the research, development and commercialization of gene therapies for the treatment of inherited retinal diseases (“IRD”). Under the terms of the Collaboration Agreement, the Company received an upfront payment of $100,000,000. The Company also receives funding for certain research, manufacturing, clinical development and commercialization costs, potential additional milestone payments upon the achievement of such milestones and royalties on future net sales of products. The Company estimates that its cash and cash equivalents on-hand at September 30, 2020 will be sufficient to cover its expenses for at least the next twelve months from the date of issuance of these condensed consolidated financial statements.

Risks and Uncertainties

The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure.

There are also many uncertainties regarding the pandemic caused by the novel coronavirus, or COVID-19, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how the pandemic will impact its financial condition, liquidity, operations, clinical studies, employees, vendors, and industry. While the pandemic did not materially affect the Company's financial results and business operations in the nine-month period ended September 30, 2020, the Company is unable to predict the impact that COVID-19 will have on its financial position and operating results in future periods due to numerous uncertainties. The Company will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to its operations as necessary.

The Company’s capital resources and operations to date have been funded primarily with the proceeds from the Collaboration Agreement and private and public equity offerings. In the future, the Company may seek to raise additional capital through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable it to complete the development and potential commercialization of its product candidates. The COVID-19 outbreak and mitigation measures also have had, and may continue to have, an adverse impact on global economic conditions, which could have an adverse effect on the Company’s ability to raise capital when needed.  

2.       Summary of Significant Accounting Policies and Recent Accounting Pronouncements:

Certain of the Company’s significant accounting policies are described below. All of the Company’s significant accounting policies are disclosed in the notes to the audited consolidated financial statements as of and for the year ended December 31, 2019 included in the Company’s Form 10-K. Since the date of such financial statements, the Company has adopted the new accounting pronouncements which are disclosed further in this note.

7

Table of Contents

Consolidation

The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries:

MeiraGTx Limited, a limited company incorporated under the laws of England and Wales;

MeiraGTx, LLC, a Delaware corporation (“Meira LLC”);

MeiraGTx UK II Limited, a limited company incorporated under the laws of England and Wales (“Meira UK II”);

MeiraGTx Netherlands, B.V., a private company with limited liability incorporated under the laws of the Netherlands (“Meira Netherlands”);

BRI-Alzan, Inc., a Delaware corporation (“BRI-Alzan”);

MeiraGTx Bio, Inc., a Delaware corporation (“Meira Bio”);

MeiraGTx B.V., a private company with limited liability incorporated under the laws of the Netherlands (“Meira B.V.”);

MeiraGTx Ireland DAC, a designated activity company incorporated under the laws of Ireland (“Meira Ireland”);

MeiraGTx Neurosciences, Inc., a Delaware corporation (“Meira Neuro”); and

MeiraGTx UK Limited, a limited company incorporated under the laws of England and Wales (“Meira UK”).

All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation.

Use of Estimates

Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these condensed consolidated financial statements, management used significant estimates in the following areas, among others: collaboration revenue, the accounting for research and development costs, share-based compensation, leases, asset retirement obligations and tax incentive receivable.

Additionally, the Company has made estimates of the impact of the COVID-19 pandemic within the condensed consolidated financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.

8

Table of Contents

Foreign Currency Contracts

The Company uses foreign currency forward contracts to protect against changes in anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, primarily associated with non-functional currency denominated expenses. The foreign currency forward contracts outstanding as of September 30, 2020 had settlement dates within three-months.  The Company does not designate its foreign currency forward contracts as part of a hedging transaction. Changes in the fair value are recorded each period within the Company’s condensed consolidated statement of operations and comprehensive loss as a component of net loss. As of September 30, 2020, the Company had £2,000,000 of futures contracts with a settlement value of $2,598,900. The fair market value of these contracts as of September 30, 2020 was $2,581,571 resulting in an unrealized loss of $17,639, which has been recognized on the balance sheet as an other current liability.

Fair Value Measurements

Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of non-performance risk including the Company’s credit risk.

The Company follows ASC Topic 820, Fair Value Measurements and Disclosures, or ASC 820, for application to financial assets and liabilities. In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;
Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The table below represents the values of the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis:

Fair Value Measurement Using:

    

    

Significant

    

Significant Other

    

Significant

September 30, 

Observable Inputs

Observable Inputs

Unobservable

Description

2020

(Level 1)

(Level 2)

(Level 3)

Restricted cash

$

250,526

$

250,526

$

$

Other current liabilities

$

17,639

$

$

17,639

$

Asset retirement obligations

$

1,741,407

$

$

$

1,741,407

Fair Value Measurement Using:

    

    

Significant

    

Significant Other

    

Significant

December 31, 

Observable Inputs

Observable Inputs

Unobservable

Description

2019

(Level 1)

(Level 2)

(Level 3)

Restricted cash

$

123,376

$

123,376

$

$

Asset retirement obligations

$

1,654,755

$

$

$

1,654,755

9

Table of Contents

Leases

The Company accounts for leases in accordance with ASC 842. The Company determines if an arrangement is a lease at contract inception. A lease exists when a contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: (1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment), and (2) the Company has the right to control the use of the identified asset. The Company accounts for the lease and non-lease components as a single lease component.

From time to time the Company enters into direct financing lease arrangements that include a lessee obligation to purchase the leased asset at the end of the lease term, a bargain purchase option, or provides for minimum lease payments with a present value of 90% or more of the fair value of the leased asset at the date of lease inception.

Operating leases where the Company is the lessee are included in right-of-use (“ROU”) assets and lease obligations are included on the Company’s consolidated balance sheets. The lease obligations are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date and subsequent reporting periods.

Finance leases where the Company is the lessee are included in ROU assets and lease obligations on the Company’s consolidated balance sheets. The lease obligations are initially measured in the same manner as for operating leases and are subsequently measured at amortized cost using the effective interest method.

Key estimates and judgments include how the Company determined (1) the discount rate used to discount the unpaid lease payments to present value, (2) lease term and (3) lease payments.

ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company’s leases where it is the lessee do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The Company uses the implicit rate when readily determinable.

The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that is reasonably certain to be exercised, or an option to extend (or not to terminate) the lease controlled by the lessor.

The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date less any lease incentives received.

For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, minus any accrued lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset, or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability.

The Company has elected not to recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less at lease commencement. Lease payments associated with short-term leases are recognized as an expense on a straight-line basis over the lease term.

10

Table of Contents

Asset Retirement Obligations

Accounting for asset retirement obligations requires legal obligations associated with the retirement of long-lived assets to be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, the Company estimates the fair value of its asset retirement obligations using Level 3 present value techniques, in which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate. Asset retirement obligations currently reported as other liabilities on the condensed consolidated balance sheet were measured during a period of historically low interest rates. The impact on measurements of new asset retirement obligations using different rates in the future may be significant.

The Company uses estimates to determine the asset retirement obligations at the end of the lease term and discounts such asset retirement obligations using an estimated discount rate. Interest on the discounted asset retirement obligation is amortized over the term of the lease using the effective interest method and is recorded as interest expense in the condensed consolidated statements of operations and comprehensive loss.

The change in asset retirement obligations is as follows:

For the Nine Months Ended September 30, 

2020

2019

Balance at beginning of period

    

$

1,654,755

    

$

128,119

Amortization of interest

 

100,847

 

7,861

Effects of exchange rate

 

(14,195)

 

(4,767)

Balance at end of period

$

1,741,407

$

131,213

Collaboration Arrangements

The Company evaluates its collaborative arrangements pursuant to ASC 808, Collaborative Arrangements (“ASC 808”) and ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company considers the nature and contractual terms of collaborative arrangements and assesses whether the arrangement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards with respect to the arrangement. If the Company is an active participant and is exposed to significant risks and rewards with respect to the arrangement, the Company accounts for the arrangement as a collaboration under ASC 808. To date, the Company has entered into two separate collaboration agreements, both of which are with Janssen, which were determined to be within the scope of ASC 808.

ASC 808 does not address recognition or measurement matters related to collaborative arrangements. Payments between participants pursuant to a collaborative arrangement that are within the scope of other authoritative accounting literature on income statement classification are accounted for using the relevant provisions of that literature. If the payments are not within the scope of other authoritative accounting literature, the income statement classification for the payments is based on an analogy to authoritative accounting literature or if there is no appropriate analogy, a reasonable, rational and consistently applied accounting policy election. Payments received from a collaboration partner to which this policy applies may include upfront payments in respect of a license of intellectual property, development and commercialization-based milestones, and royalties.

Refer to the discussion in Note 8 for further information related to the accounting for the Janssen Collaboration Agreement.

11

Table of Contents

Revenue Recognition

Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering committees. The Company evaluates the promised goods or services to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.

When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.

The Collaboration Agreement with Janssen is accounted for under ASC 808, however, as ASC 808 does not address recognition or measurement matters such as determining the appropriate unit of accounting or when the recognition criteria are met, the Company accounts for the consideration received from Janssen in accordance with ASC 606. In accordance with ASC 606, the Company recognizes revenue when its customer or collaborator obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps:

i.identify the contract(s) with a customer;
ii.identify the performance obligations in the contract;
iii.determine the transaction price;
iv.allocate the transaction price to the performance obligations within the contract; and
v.recognize revenue when (or as) the entity satisfies a performance obligation.

The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.

At contract inception, once the contract is determined to be by analogy within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements typically consist of a license to the Company’s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources, and (ii) is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are

12

Table of Contents

combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.

The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.

Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company’s condensed consolidated balance sheet. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue – related party, current. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue – related party.

The Company’s collaboration revenue arrangements include the following:

Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.

13

Table of Contents

Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any revenue related to sales-based royalties or milestone payments based on the level of sales.

Research and Development Services: The Company is incurring research and development costs, with Janssen responsible for up to 100% of the costs, depending on the type of research and development services being performed. The Company records costs associated with the development activities as research and development expenses in the condensed consolidated statements of operations and comprehensive loss consistent with ASC 730, Research and Development. The reimbursement of the research and development costs by Janssen is representative of the joint risk sharing nature of the arrangement. The Company considered the guidance in ASC 808 and recognizes the payments received from Janssen as a reduction to research and development expense when the related costs are incurred.

Research and Development

Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses, including salaries, benefits and travel of the Company’s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies and for the drug product for the clinical studies and preclinical activities; facilities; supplies; rent, insurance, certain legal fees, share-based compensation, depreciation and other costs associated with clinical and preclinical activities and regulatory operations. Research funding under collaboration agreements and refundable research and development credits / tax credits are recorded as an offset to these costs.

Costs for certain development activities, such as Company funded outside research programs, are recognized based on an evaluation of the progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid expenses or accrued expenses, as the case may be.

Net Loss per Ordinary Share

Basic net loss per ordinary share is computed by dividing net loss by the weighted average number of shares of the Company’s ordinary shares assumed to be outstanding during the period of computation. Diluted net loss per ordinary share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional ordinary shares that would have been outstanding if the potential ordinary shares had been issued at the beginning of the year and if the additional ordinary shares were dilutive (treasury stock method) or the two-class method, whichever is more dilutive. For all periods presented, basic and diluted net loss per ordinary share are the same, as any additional ordinary share equivalents would be anti-dilutive.

The following securities are considered to be ordinary share equivalents, but were not included in the computation of diluted net loss per ordinary share because to do so would have been anti-dilutive:

    

September 30, 

    

September 30, 

    

2020

    

2019

Restricted share units

545,000

Share options

 

4,970,531

 

3,723,697

Restricted ordinary shares subject to forfeiture

326,588

 

5,515,531

 

4,050,285

14

Table of Contents

Segment Information

Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations.

The Company’s license revenue, research funding and deferred revenue from its Collaboration Agreement are generated in the United Kingdom.

The following table summarizes non-current assets by geographical area:

    

September 30, 

    

December 31, 

2020

2019

United States

$

14,299,510

$

14,354,792

United Kingdom

 

39,755,612

 

39,476,700

Ireland

19,752,062

Netherlands

 

1,356,396

 

1,076,286

$

75,163,580

$

54,907,778

Accounting Pronouncements Recently Adopted

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurements, which changes the fair value measurement disclosure requirements of ASC 820. The goal of the ASU is to improve the effectiveness of ASC 820’s disclosure requirements by providing users of the financial statements with better information about assets and liabilities measured at fair value in the financial statements and notes thereto. The guidance is applicable for fiscal years beginning after December 15, 2019 and interim periods within those years. The adoption of the provisions of ASU 2018-13 did not have a material impact on the current financial statements.

In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”). The standard amends ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers, to clarify the interaction between collaborative arrangement participants that should be accounted for as revenue under ASC 606. In transactions when the collaborative arrangement participant is a customer in the context of a unit of account, revenue should be accounted for using the guidance in Topic 606. The amendments in ASU 2018-18 are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of ASU 2018-18 did not have a material impact on the current financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which adds a new Topic 326 to the Codification and removes the thresholds that companies apply to measure credit losses on financial instruments measured at amortized cost, such as loans, receivables, and held-to-maturity debt securities. Under current GAAP, companies generally recognize credit losses when it is probable that the loss has been incurred. The revised guidance will remove all recognition thresholds and will require companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU 2016-13 also amends the credit loss measurement guidance for available-for-sale debt securities and beneficial interests in securitized financial assets. The guidance is applicable for fiscal years beginning after December 15, 2019 and interim periods within those years, however, the FASB extended the effective date for smaller reporting companies to fiscal years beginning after December 15, 2022. The Company is currently evaluating the potential impact of the adoption of this standard on its related disclosures.  

15

Table of Contents

3.       Asset Acquisition

On April 9, 2020 (the “Closing Date”), the Company acquired Emrys Bio Inc. (“Emrys”), a pre-clinical biopharmaceutical company developing brain-derived neurotrophic factor gene therapy for treatment of genetic obesity disorders, as well as the development of gene therapy product candidates for other central nervous system diseases. The Company acquired Emrys pursuant to an Agreement and Plan of Merger (the “Emrys Merger Agreement”), dated as of April 9, 2020, by and among the Company, Emrys, and EB Acquisition, Inc., a wholly-owned subsidiary of the Company (“Merger Sub”), the Emrys stockholders and the Emrys stockholder representative, pursuant to which Merger Sub was merged with and into Emrys, with Emrys being the surviving corporation (the “Merger”). As a result of the Merger, Emrys became a wholly-owned subsidiary of the Company and was renamed MeiraGTx Bio, Inc.

As part of the entry into the Emrys Merger Agreement, the parties to the Agreement and Plan of Merger (the “Vector Merger Agreement”), dated October 5, 2018, entered into an Amendment and Waiver to the Vector Merger Agreement by and among the Company, VN Acquisition, Inc., VN Acquisition 2, Inc., the former Vector Neurosciences Inc. (“Vector”) stockholders and the Vector stockholder representative, to terminate and waive all milestone payments payable under the Vector Merger Agreement that were otherwise required if specified regulatory milestones were met, and to terminate and waive all royalty payments that were otherwise required to be paid under the Vector Merger Agreement. Several of the selling Emrys stockholders were also stockholders of Vector.

In connection with the acquisition of Emrys and the termination and waiver of the milestone and royalty payments otherwise required under the Vector Merger Agreement, the consideration to Emrys selling stockholders consisted of an aggregate of 580,000 of the Company’s ordinary shares of which (i) 232,000 ordinary shares were issued on the Closing Date, (ii) 290,000 restricted ordinary shares were issued on the Closing Date, with 50% of such restricted ordinary shares scheduled to vest on each of the first and second anniversaries of the Closing Date, and (iii) 58,000 ordinary shares will be issued 18 months following the Closing Date, provided that the shares described in clauses (ii) and (iii) are subject to certain indemnification claims under the Emrys Merger Agreement.  Total consideration of $7,685,001 was based on the closing price of the Company’s ordinary shares of $13.25 per share on the Closing Date.  

The Company determined this transaction represented an asset acquisition as substantially all of the value was in the intellectual property as defined by ASC 805, Business Combinations (“ASC 805”). The asset acquisition of in process research and development was recorded at a fair value of $7,685,001 as of April 9, 2020. The acquired in process research and development was immediately charged to research and development expense in the condensed consolidated statement of operations and comprehensive loss as of the acquisition date since the Company determined that there was no additional alternative use of these assets.

4.       Accrued Expenses

Accrued expenses for the periods presented are comprised of the following:

    

September 30, 

    

December 31, 

2020

2019

Clinical trial costs

$

8,512,457

$

7,788,077

Professional fees

 

2,082,931

 

486,743

Fixed assets

 

1,124,566

 

1,108,362

Research and development

 

877,051

 

Compensation and benefits

867,584

6,850,335

Manufacturing costs

 

750,282

 

Consulting

 

703,439

 

1,247,989

Rent

 

9,036

 

283,876

Other

 

636,136

 

318,375

$

15,563,482

$

18,083,757

16

Table of Contents

5.       Share-Based Compensation

Equity Incentive Plans

The Company’s 2018 Incentive Award Plan and 2016 Equity Incentive Plan (collectively, the “Plans”) were adopted by the Company’s board of directors and shareholders. Under the Plans, the Company has granted share options and restricted share units (“RSUs”) to selected officers, employees and non-employee consultants. The Company’s board of directors or a committee thereof administers the Plans. Upon the adoption of the 2018 Incentive Award Plan, the Company ceased issuing awards under the 2016 Equity Incentive Plan.

Options

A summary of the Company’s share option activity related to employees, non-employee members of the board of directors and non-employee consultants as of and for the year-ended December 31, 2019 and the nine-month period ended September 30, 2020 is as follows:

Weighted-

    

    

Weighted-

    

Average

Average

Remaining